An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

• Main Authors: Alexander D. James (Author), Hilmar Schiller (Author), Cyrille Marvalin (Author), Yi Jin (Author), Hubert Borell (Author), Ad F. Roffel (Author), Ulrike Glaenzel (Author), Yan Ji (Author), Gian Camenisch (Author)
• Format: Book
• Published: Wiley, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or metastatic breast cancer. A human ADME study was conducted in healthy male volunteers following a single oral...